CLINICAL ONCOLOGY
The OTD team (composed of MD, PhD or MSc) has collective experience managing over 60 worldwide Phase I-II oncology clinical trials, including several first-in-man molecules. We have solid international experience collaborating with small biotech companies, mid-size and large pharmaceutical organizations, academic institutions, CROs and a wide selection of hospitals and clinics, contributing to an extensive international network. Our collective strength lies in our diverse backgrounds, extensive oncology experience and high-level training.
As a small and flexible boutique CRO, we:
TUMOR TYPES AND THERAPIES
Solid tumors: Bladder, breast, cholangiocarcinoma, colorectal, glioblastoma, head & neck, hepatoma, lung, melanoma, ovary, pancreatic, prosate, renal, sarcomas, stomach, thyroid, and rare tumor types (eg, NMC)
Hematologic malignancies: leukemia (ALL, AML), Hodgkin’s and non-Hodgkin’s lymphomas, β-hemoglobinopathies (SCA and β-thalassemia major), myeloproliferative disorders
Monotherapy/Combinations: classic cytotoxics, targeted therapeutic agents (small molecules and monoclonal antibodies), hormonal therapies, cell-based therapies, vaccines
